Developing a new HIV-1 vaccine using mRNA technology
SOSIP-NP/mRNA combination for novel preventive and therapeutic HIV-1 vaccine regimens
['FUNDING_OTHER'] · DUKE UNIVERSITY · NIH-10866596
This study is exploring a new type of vaccine using mRNA technology to help prevent and treat HIV-1, and it's designed for people living with or at risk of HIV, aiming to boost the immune system's ability to fight the virus.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DUKE UNIVERSITY (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-10866596 on ClinicalTrials.gov |
What this research studies
This research aims to create a novel vaccine regimen for preventing and treating HIV-1 by utilizing mRNA technology. The approach involves testing new vaccine constructs that can stimulate the immune system to produce both antibodies and cellular responses against the virus. The research will be conducted using non-human primate models to evaluate the effectiveness of these vaccines in controlling HIV-1 infection and reducing viral reservoirs. If successful, this could lead to significant advancements in HIV prevention and treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at high risk for HIV infection or those living with HIV who are seeking new treatment options.
Not a fit: Patients who are not at risk for HIV or those who are already effectively managing their HIV with current therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking vaccine that significantly reduces the incidence of HIV infections and improves treatment outcomes for those living with the virus.
How similar studies have performed: Other research has shown promise with mRNA technology in vaccine development, particularly in the context of infectious diseases, indicating potential for success in this novel approach.
Where this research is happening
DURHAM, UNITED STATES
- DUKE UNIVERSITY — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WILLIAMS, WILTON B — DUKE UNIVERSITY
- Study coordinator: WILLIAMS, WILTON B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome, Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome, Acquired Immunodeficiency Syndrome Virus